Prion diseases are neurodegenerative disorders characterized by the aggregation of abnormally folded prion protein (PrP Sc ). In this study, we focused on the mechanism of clearance of PrP Sc , which remains unclear. p62 is a cytosolic protein known to mediate both the formation and degradation of aggregates of abnormal proteins. The levels of p62 protein increased in prion-infected brains and persistently infected cell cultures. Upon proteasome inhibition, p62 co-localized with PrP Sc , forming a large aggregate in the perinuclear region, hereafter referred to as PrP Sc -aggresome. These aggregates were surrounded with autophagosome marker LC3 and lysosomes in prion-infected cells. Moreover, transient expression of the phosphomimic form of p62, which has enhanced ubiquitin-binding activity, reduced the amount of PrP Sc in prion-infected cells, indicating that the activation of p62 could accelerate the clearance of PrP Sc . Our findings would thus suggest that p62 could be a target for the therapeutic control of prion diseases.
, forming a large aggregate in the perinuclear region, hereafter referred to as PrP Sc -aggresome. These aggregates were surrounded with autophagosome marker LC3 and lysosomes in prion-infected cells. Moreover, transient expression of the phosphomimic form of p62, which has enhanced ubiquitin-binding activity, reduced the amount of PrP Sc in prion-infected cells, indicating that the activation of p62 could accelerate the clearance of PrP Sc . Our findings would thus suggest that p62 could be a target for the therapeutic control of prion diseases. P rion diseases are fatal neurodegenerative disorders associated with the conformational conversion of normal cellular prion protein (PrP C ) to b-sheet-rich pathogenic prion protein (PrP Sc ) 1 . The histopathological hallmarks of prion diseases are spongiform changes, marked neuronal loss and gliosis. In addition, large amyloids composed of PrP Sc can be observed in most affected brains 2, 3 . However, the role of these aggregates in the pathogenesis remains to be elucidated. Although the formation of neuronal inclusion bodies might be a protective reaction of cells to reduce the levels of toxic forms of abnormal proteins 4 , it was reported that b-sheet-rich PrP inhibits the catalytic activity of proteasomes 5 , leading to a disruption of protein homeostasis. As the ubiquitinproteasome system (UPS) is essential in the degradation of abnormal proteins, its impairment has been implicated in the ''conformational'' disorders such as Huntington's disease, Parkinson's disease and Alzheimer's disease 6 , in which misfolded proteins are known to make aggregates. As the aggregates contain polyubiquitinated proteins and also proteasomes, their build-up promotes a vicious cycle in which the UPS becomes still further hampered 7 . When the UPS is disrupted, ubiquitinated proteins are transported to the perinuclear region via a dynein-dependent retrograde transport system, where they form large complexes termed aggresomes [8] [9] [10] . p62, which was originally identified as adapter proteins involved in multiple cell-signaling pathways, has recently been reported to function in the formation of aggresomes. It has also been shown that p62 binds to ubiquitin and interacts with an autophagosomal membrane protein, microtubule-associated protein 1 light chain 3 (LC3-II) [11] [12] [13] [14] . Thus, aggregated proteins sequestered by p62 are degraded through the autophagolysosomal pathway 15, 16 . Interestingly, p62 has also been found in neuronal inclusion bodies with ubiquitinated protein aggregates in Alzheimer's disease, Pick's disease, dementia with Lewy bodies, Parkinson's disease, frontotemporal lobar degeneration, and amyotrophic lateral sclerosis (ALS) [17] [18] [19] [20] [21] [22] . It has been reported that PrP Sc degradation is accelerated by activation of autophagy [23] [24] [25] , however the mechanism of clearance of PrP Sc aggregates has not been fully elucidated. In this study, we investigated the role of p62 in prion-infected cell culture models and found that p62 was co-localized with PrP Sc -aggresomes, and that the activation of p62 was able to reduce the accumulation of PrP Sc .
Results
Up-regulation of p62 was observed following prion infection. To investigate the expression levels of p62 protein in prion-infected mice, we intracerebrally inoculated 22 L prions into ddY mice (n 5 3) and examined the levels of p62 protein in the brains of terminally sick mice by immunoblotting. Significantly up-regulated p62 was observed in the brains of 22L-inoculated mice, compared with that of the control mice (Fig. 1a) . Up-regulated LC3-II was also observed, suggesting the involvement of autophagic degradation.
We next intraperitoneally inoculated 263 K prions into Syrian hamsters and examined the levels of p62 protein in the brains of terminally sick hamsters by immunoblotting. The levels of p62 also increased in the brains of 263K-inoculated hamsters, compared with those of the control hamsters (Fig. 1b) . The presence of PrP Sc was identified in all infected brains.
For further experiments, we used ScN2a58 cells, persistently 22L-infected N2a58 cells, containing high amounts of PrP Sc . Immunoblotting revealed that the levels of p62 protein also increased in ScN2a58 cells compared with uninfected N2a58 cells (Fig. 2a) . Moreover, the levels of p62 mRNA also significantly increased in ScN2a58 cells (Fig. 2b) .
As microglia are known to play a major role in initiating the pathological changes in prion disease, we investigated the effects of prion infection on p62 using a microglial cell line (MG20). We added 0.1% brain homogenates from 22L-infected mice (22 L BH) or normal mice (nBH) to MG20 cells. After serial passages, the presence of PrP Sc and up-regulation of p62 were identified in the 22L-infected cells from passage 3 (Fig. 2c) , indicating that the phenomenon was not neuron-specific. Taken together, these data showed that up-regulation of p62 subsequently occurs in vivo and in vitro due to prion infection.
p62 co-localizes with PrP
Sc in prion-infected cells. It has been reported that PrP C is retrogradely transported from the endoplasmic reticulum (ER) and accumulates in the cytosol as proteaseresistant and detergent-insoluble PrP upon proteasome inhibition 26 , and that aggregates may contain ubiquitinated proteins 27 . Another reports suggest that some of the PrP aggregates contain uncleaved signal peptides after proteasome inhibition, indicating the existence of ERAD-independent mechanism in which PrP fails to translocate into the ER lumen [28] [29] [30] . To determine whether such PrP aggregates are recognized by p62, we investigated the subcellular localization of total PrP and p62 in N2a58 and ScN2a58 cells by immunofluorescence staining. Under normal conditions, immunofluorescence for total PrP was greater in ScN2a58 cells than in N2a58 cells [ Fig. 3a, MG132 (-) ]. In both cell types, endogenous p62 was distributed throughout the cytoplasm [Fig. 3a, MG132 (-) ], consistent with previous observations 11, 14, 31 . When we treated N2a58 and ScN2a58 cells with a chemical proteasome inhibitor, MG132 (10 mM, 24 h) to see how the impairment of UPS affects the distribution of PrP and p62, singular p62-containing inclusions were frequently induced at the perinuclear region in both cell types [ Fig. 3a, MG132 (1 (Fig. 3b) . Upon proteasome inhibition, a large PrP aggregate formed in the perinuclear region, hereafter referred to as ''PrP Scaggresome'', and importantly, p62 relocalized to PrP Sc -aggresome. (Fig. 3b) .
We next investigated whether the knockdown of p62 affects the formation of PrP Sc -aggresome. We treated p62-specific siRNA or control siRNA to ScN2a58 cells (50 nM, 48 h), following MG132 treatment (10 mM, 24 h). As expected, in control siRNA-treated cells, the PrP Sc -aggresomes formed after proteasome inhibition (Fig. 4) . In contrast, in p62 siRNA-treated cells, in which p62 fluorescence was successfully decreased, PrP Sc -aggresomes did not form, suggesting the presence of p62 to be crucial for PrP Sc -aggresome formation.
p62 relocalized to PrP Sc -aggresomes through ubiquitin-binding. p62 is known to interact with ubiquitinated proteins through its Cterminus ubiquitin-associated domain (UBA) 33 . To investigate whether or not the co-localization of p62 and PrP Sc was dependent on the domain, we introduced expression vectors of HA-tagged p62 or UBA domain-deleted p62 (p62DUBA, missing amino acids 388-442) into ScN2a58 cells and visualized p62 and PrP Sc . As expected, HA-tagged p62 relocalized to PrP Sc -aggresomes upon proteasome inhibition (Fig. 5) . In contrast, HA-tagged p62DUBA did not relocalize to PrP Sc -aggresomes, suggesting that the UBA domain plays a critical role in p62 recruitment to PrP Sc -aggresomes. The levels of p62 protein increased by MG132 (10 mM, 24 h), and ubiquitinated proteins with high-molecular-weight (HMW, ,250 kDa), which are likely to derive from the aggresomes, were evident in ScN2a58 cells (Fig. S1 ), suggesting that PrP Sc -aggresomes contain large ubiquitinated proteins.
PrP is co-immunoprecipitated with p62. We next performed coimmunoprecipitation experiments using ScN2a58 cell lysates. Endogenous p62 was co-immunoprecipitated with anti-PrP antibody (SAF32) both without (Fig. S2 , top left) and with proteasome inhibition (Fig. S2, top right) . The presence of PrP in SAF32 immunoprecipitates was also identified in both lysates (Fig. S2,  bottom) .
p62-positive aggresomes in prion-infected cells are surrounded by lysosomes. We next investigated the localization of such aggresomes and lysosomes in ScN2a58 cells, and we showed that p62-positive aggresomes were surrounded by lysosomes (Fig. 6a) . Similar result was obtained in PrP-positive aggresomes (Fig. 6b) . We also observed that LC3 was concentrated in the aggresomes (Fig. 6c) . These results suggest that such aggresomes are potentially degraded in lysosomes.
p62 is involved in the degradation of PrP Sc . To investigate whether overexpression of p62 affects the degradation of PrP Sc , a HA-tagged p62 was introduced into N2a58 cells or ScN2a58 cells, and the amount of PrP Sc was analyzed. Transient expression of p62 had no effect on the amount the amount of PK-resistant PrP (Fig. 7a) . It has been shown that the activity of p62 appears to be controlled by phosphorylation at serine 403 (S403) of the human p62 UBA domain due to enhancement of its affinity to polyubiquitin, promoting efficient autophagic degradation of ubiquitinated proteins 34 . To investigate whether phosphorylation of the UBA domain affects the clearance of PrP Sc , a HA-tagged phosphomimic mutant, with the substitution of mouse p62 serine 405 for glutamate (corresponding to S403 in human p62) (Fig. 7b) , was introduced into ScN2a58 cells and the amount of PrP Sc was analyzed. Transient expression of phosphomimic p62-HA reduced the amount of PrP Sc in ScN2a58 cells (Fig. 7c) . To confirm whether the mutation enhanced the affinity between p62 and ubiquitinated proteins, the lysates from transfected cells were immunoprecipitated with anti-HA antibody, and ubiquitinated proteins in the immunoprecipitates were detected by immunoblotting. As expected, the amount of ubiquitinated proteins in phosphomimic p62 transfected cells was greater than those in mock or wild-type transfected cells (Fig. 7d) . In addition, after the blocking of lysosomal degradation by ammonium chloride, phosphomimic p62 was largely localized in lysosomes (Fig.  S3) . Taken together, these results suggest that phosphomimic p62 accelerated the clearance of PrP Sc in lysosomes.
Discussion
Our study revealed the following.
(1) p62 increased in association with prion-infection in cell cultures and brains ( Fig. 1 and 2) ; (2) Large PrP Sc aggregates encircled by p62 form when the UPS is disrupted (Fig. 3b) ; (3) The interaction of p62 with polyubiquitin is crucial to the formation of PrP Sc -aggresomes (Fig. 5) ; and (4) the constitutively active form of p62 could reduce the amount of PrP Sc in infected cells (Fig. 7c) . These findings suggest that p62-mediated aggresome-formation could be important in the host-defense response against prion infection.
Contrary to our data, Xu et al 35 previously reported that the levels of p62 protein and ubiquitinated proteins were decreased in the brains of 263K-infected hamsters. This discrepancy is unknown, but may be related to the differences in the experimental conditions. 
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Several different reports have described that the levels of p62 protein are known to be increased when proteasome function is inhibited 18, 20, 36 . In prion-infected animal brains, proteasome activities are known to be reduced, and it has been clearly evidenced that PrP Sc binds to the 20S core particle of proteasomes in vitro 37 and inhibit proteasome activity in neurons 5 . Actually, it has recently been reported that transcription factor NF-E2-related factor 2 (Nrf2), which enhances the expression of p62 38 , was activated when the UPS is impaired 39 . Furthermore, as p62 interacts with Keap1, which regulates the turnover of Nrf2, the up-regulated p62 may competitively inhibit the Nrf2-Keap1 interaction, resulting in stabilization of Nrf2 followed by transcriptional activation of p62 40 . This positive feedback loop may contribute to the up-regulation of p62 demonstrated in this study in the large PrP Sc -aggresomes forming in infected cells when proteasomes were inhibited by MG132. These findings suggest that direct inhibition of the UPS by PrP Sc prompts the up-regulation of p62 as a compensatory mechanism of the UPS in prion diseases.
It is well known that p62 can bind to polyubiquitinated proteins and play a role in the degradation of misfolded proteins such as the polyglutamine-expanded huntingtin 34 .
Relatively large PrP
Sc -aggresomes encircled by p62 were observed in infected cells when the UPS was disrupted, suggesting that p62 mediates PrP Sc -aggresome formation (Fig. 3b) . Because it is not clear whether PrP
Sc itself is ubiquitinated or not, we cannot exclude the possibility that p62 binds indirectly with PrP Sc . It is likely that the formation of p62-PrP complexes is dependent upon the presence of other ubiquitinated proteins in the PrP Sc -aggresomes because these are often observed in PrP plaques in CJD brains 41, 42 . Based on the fact that the phosphomimic p62, which has enhanced ubiquitin-binding activity, promoted the clearance of PrP Sc (Fig. 7c) , we came to the conclusion that activation of p62 is important for the efficient clearance of PrP Sc . It has been reported that p62 and its association with ubiquitin is involved in the clearance of neuronal inclusion bodies such as asynuclein 43 , polyglutamine-expanded huntingtin 34 and androgen receptor 44 , through the autophagy-lysosome pathway. In addition, it has very recently reported overexpression of p62 promotes the degradation of some mutant PrPs such as PrP-PG14, a PrP mutant with the extra nine-octapeptide insertion associated with genetic CJD and PrP-CYTO, a PrP mutant without signal peptide and GPI anchor 45 . In our study, we have provided evidence that overexpression of p62 promotes the degradation of pathogenic prion protein, although the effect is limited to phosphomimic form of p62. Taking into account that non-phosphorylated p62 has relatively low affinity for ubiquitin, phosphorylation of p62 is important for the efficient degradation.
In conclusion, disruption of the UPS may be involved in prion pathogenesis, while the enhancement of p62-activity is a possible therapeutic target for the induction of the autophagic clearance of pathogenic prion proteins.
Methods
Antibodies. Anti-p62/SQSTM1 (MBL, PM045), anti-b-actin (Sigma-Aldrich), anti-HA (Invitrogen), anti-ubiquitin (Santa Cruz Biotechnology, P4D1), anti-LC3B (Cell Signaling Technology, #2775), and anti-PrP (Santa Cruz Biotechnology, M20; SPIBio, SAF61 and SAF32; SIGNET, 3F4) antibodies were purchased from the indicated vendors. Horseradish peroxidase-conjugated anti-goat (Santa Cruz Biotechnology), anti-mouse and anti-rabbit IgG antibodies (GE Healthcare Life Sciences) were used for immunoblotting. Alexa FluorH 488-conjugated anti-mouse IgG and Alexa FluorH 594-conjugated anti-rabbit IgG antibodies (Invitrogen) were used for immunofluorescence analysis.
Cell cultures. The mouse neuroblastoma Neuro 2a cells were obtained from the American Type Culture Collection (CCL 131). N2a58 cells are mouse PrP C overexpressing Neuro 2a cells, and ScN2a58 cells originated from N2a58 cells infected with a mouse-adapted scrapie strain, 22 L, as previously described 46, 47 . The cells were cultured in Dulbecco's modified Eagle's medium (DMEM; Sigma-Aldrich) containing 10% heat-inactivated fetal bovine serum (FBS) and penicillinstreptomycin (Invitrogen). MG20 cells (a gift from Dr. Iwamaru), isolated from neonatal tga20 mice that overexpress mouse PrP C48 , were cultured in DMEM containing 10% heat-inactivated FBS, penicillin-streptomycin, 2-mercapto-ethanol and insulin. All cultured cells were maintained at 37uC in 5% CO 2 in the biohazard prevention area of Nagasaki University.
Plasmids and siRNA. Mouse p62 open reading frame was amplified from N2a58 cDNA with primers of mp62-BamHI-F (59-cgcggatccgcggttatggcgtcgttcacg-39) and mp62-XhoI-R (59-ccgctcgagtcattaagcgtaatctggaacatcgtatgggtacaatggtggagggtgctt-39). UBA domain-deleted p62 (p62DUBA, missing amino acids 388-442) was amplified with primers of mp62-BamHI-F and mp62DUBA-XhoI-R (59-ccgctcgagtcattaagcgtaatctggaacatcgtatgggtaatgtgggtatagggcagcttc-39). phosphomimic p62 was amplified with primers of mp62 (S405E)-BamHI-F (59-tcccagatgctggagatgggcttctctgat-39) and mp62 (S405E)-XhoI-R (59-atcagagaagcccatctccagcatctggga-39). Amplified PCR fragments were inserted into the BamHI and XhoI sites of expression plasmid pcDNA3.1 (Invitrogen) and confirmed by sequential analysis. Immunoblotting. Immunoblotting analysis was performed as previously described 49 . Briefly, samples were lysed with cold lysis buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.5% Triton X-100, 0.5% sodium deoxycholate, 2 mM EDTA) containing protease inhibitors (Nacalai Tesque, Inc., Kyoto, Japan) for 30 min at 4uC. After 10 min of centrifugation at 15,000 3 g, the supernatant was collected, and the concentration of total protein was measured using BCA Protein Assay Kit (Pierce).
For PrP
Sc detection, samples were digested with 40 mg/ml of proteinase K (PK; SigmaAldrich) at 37uC for 30 min, boiled for 5 min with SDS loading buffer (50 mM TrisHCl pH 6.8, 5% glycerol, 1.6% SDS, 100 mM dithiothreitol), and subjected to SDS-PAGE. The proteins were transferred onto an Immobilon-P Membrane (Millipore) in transfer buffer containing 15% methanol at 300 mA for 90 min; the membrane was blocked with 5% nonfat dry milk in TBST (10 mM Tris-HCl pH 7.8, 100 mM NaCl, 0.1% Tween 20) for 30 min at room temperature and further incubated with primary antibodies. The immunoreactive bands were visualized using ECL Western Blotting Detection Kit (GE Healthcare Life Sciences).
Real-time PCR. Total RNA was isolated from cells using a TRIZOLH Reagent (Invitrogen). The first-strand cDNA was synthesized from 2 mg of total RNA with Super Script III Reverse Transcriptase (Invitrogen). The primers were: 59-gctgccctatacccacatct-39 and 59-cgccttcatccgagaaac-39 for p62 and 59-aaatcgtgcgtgacatcaaa-39 and 59-aaggaaggctggaaaagagc-39 for b-actin. b-actin mRNA was determined as a positive control. For real-time PCR, the synthesized cDNA was reacted with Fast Start Universal SYBR Green Master (Roche Applied Science) and measured by Light CyclerH 480 (Roche Applied Science).
Immunofluorescence analysis. Cells were fixed for 30 min at room temperature in 4% formaldehyde in PBS, permeabilized for 5 min at room temperature with 0.5% Triton X-100 in PBS, treated with 3 M guanidine thiocyanate for 5 min, blocked for 1 h at room temperature in TBST containing 5% skim milk, and incubated overnight at 4uC with the primary antibody in TBST containing 1% skim milk. After three washes in PBS, cells were incubated with the appropriate Alexa FluorH-conjugated secondary antibodies (dilution 15200) for 90 min at 37uC. For lysosomal staining, cells were stained with LysotrackerH dye (prepared according to kit instructions) for 30 min at 37uC. All images were obtained using a confocal laser-scanning microscope (Carl Zeiss).
Co-immunoprecipitation. ScN2a58 cells were grown to confluence in a 60 mm dish and treated with MG132 (10 mM, 24 h), and then harvested. Cells were lysed using cold immunoprecipitation lysis buffer (150 mM NaCl, 10 mM EDTA, 10 mM KH 2 PO 4 pH 7.5) containing 2% Triton X-100. Cell debris was removed by centrifugation and the lysates were pre-cleaned for 30 min with protein GSepharose TM 4 Fast Flow (GE Healthcare Life Sciences). After the protein GSepharose was removed by centrifugation, the supernatant was incubated at 4uC with anti-p62 or anti-rabbit IgG antibodies for 2 h. Protein G-Sepharose was then added to the supernatant and incubation was continued for another 1 h. The immunoprecipitates were washed six times with washing buffer (150 mM NaCl, 10 mM Tris-HCl pH 7.4, 0.2% Tween-20), and resuspended in 2 3 loading buffer.
In vivo infection experiments. Four-weeks-old ddY mice were purchased from SLC (Hamamatsu, Japan) and were intracerebrally inoculated with 20 mL of a 10 dilution of brain homogenate prepared from mice terminally sick with 22 L strain. As a control, age-and strain-matched mice were intracerebrally inoculated with phosphate buffered saline. The brains of the mice were removed at the terminal stage of disease. Animals were cared for in accordance with the Guidelines for Animal Experimentation of Nagasaki University. 
